Cargando…
Biosimilars: potential implications for clinicians
With the expiration of patent protection for several biologics looming, the production of highly similar therapeutic agents has begun to emerge on the pharmaceutical market. These alternative drugs are referred to as biosimilars. Many anticipate that the introduction of these agents will result in a...
Autores principales: | Eleryan, Misty G, Akhiyat, Sophia, Rengifo-Pardo, Monica, Ehrlich, Alison |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918734/ https://www.ncbi.nlm.nih.gov/pubmed/27382321 http://dx.doi.org/10.2147/CCID.S91691 |
Ejemplares similares
-
A case of eosinophilic annular erythema as a presenting sign for autoimmune hepatitis
por: Awosika, Olabola, et al.
Publicado: (2017) -
Profile of dupilumab and its potential in the treatment of inadequately controlled moderate-to-severe atopic dermatitis
por: Awosika, Olabola, et al.
Publicado: (2018) -
Review of applications of microneedling in dermatology
por: Iriarte, Christopher, et al.
Publicado: (2017) -
Biosimilar insulins: guidance for data interpretation by clinicians and users
por: Heinemann, L., et al.
Publicado: (2015) -
Biosimilar Insulins – What a Clinician Needs to Know?
por: Ghosh, Sujoy, et al.
Publicado: (2019)